Trial Profile
Phase II study of Bevacizumab in combination with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Jun 2011
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Docetaxel (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 07 Jun 2011 New trial record